FDA expands approval of uncomplicated influenza treatment Xofluza (baloxavir marboxil) to include post-exposure prevention
FDA states expanded indication for this oral antiviral which prevents virus replication by inhibiting cap-dependent endonuclease, will provide important option to help prevent influenza just in time for flu season in US, anticipated to be unlike any other because of coronavirus .
Source:
US Food and Drug Administration
SPS commentary:
European CHMP also recommended baloxavir marboxil for treatment and post-exposure prophylaxis of uncomplicated influenza earlier this month.